COLL News and Press, Collegium Pharmaceutical Inc. From 08/16/21

STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 mil...

Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...

Gainers: SCWorx (NASDAQ:WORX) +28%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +21%, BeyondSpring (NASDAQ:BYSI) +13%, Intersect ENT (NASDAQ:XENT) +12%, Caribou Biosciences (NASDAQ:CRBU) +11%. Losers: Dicerna Pharmaceuticals (NASDAQ:DRNA) -35%, iCAD (NAS...

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Collegium Pharmaceutical, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Collegium Pharmaceutical, inc (NASDAQ: COLL) Q2 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Collegium Pharmaceutical, inc (COLL) Q2 2021 Earnings Call Tra...

Collegium Pharmaceutical (NASDAQ:COLL): Q2 Non-GAAP EPS of $1.52 beats by $0.57; GAAP EPS of $1.79 beats by $1.43. Revenue of $82.94M (+6.3% Y/Y) misses by $1.65M. Press Release For further details see: Collegium Pharmaceutical EPS beats by $0.57, misses on revenue

– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue Guidance Updated ȁ...

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results and prov...

Collegium Pharmaceutical continues to move closer to achieving their mission of becoming the market leader in responsible pain management. Collegium reported a strong beat on their Q1 EPS and revenue. Xtampza ER is rapidly accruing market share and record all-time highs in total presc...

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza ® ER and O...